Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin versus lomustine for recurrent intracranial glioblastoma multiforme
2005-004627-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Enzastaurin with Lomustine (2 arms). Primary endpoint: Progression-free survival. Started Jan 2006; status: completed.
02
Drugs
enzastaurinlomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2005-004627-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004627-18.